Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
To determine the protective potential of the humoral immune response against HIV-1 in vivo
we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in …
we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in …
[HTML][HTML] Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies
…, M Schanz, L Reynell, HF Günthard, P Rusert… - PLoS …, 2012 - journals.plos.org
HIV is known to spread efficiently both in a cell-free state and from cell to cell, however the
relative importance of the cell-cell transmission mode in natural infection has not yet been …
relative importance of the cell-cell transmission mode in natural infection has not yet been …
[HTML][HTML] Determinants of HIV-1 broadly neutralizing antibody induction
Broadly neutralizing antibodies (bnAbs) are a focal component of HIV-1 vaccine design, yet
basic aspects of their induction remain poorly understood. Here we report on viral, host and …
basic aspects of their induction remain poorly understood. Here we report on viral, host and …
Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations
…, M Däumer, C Beisel, P Rusert… - Nucleic acids …, 2014 - academic.oup.com
Next-generation sequencing (NGS) technologies enable new insights into the diversity of
virus populations within their hosts. Diversity estimation is currently restricted to single-…
virus populations within their hosts. Diversity estimation is currently restricted to single-…
[HTML][HTML] Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
…, S Epp, A Audigé, J Weber, P Rusert… - The Journal of …, 2022 - Am Soc Clin Investig
BACKGROUND Neutralizing antibodies are considered a key correlate of protection by
current SARS-CoV-2 vaccines. The manner in which human infections respond to therapeutic …
current SARS-CoV-2 vaccines. The manner in which human infections respond to therapeutic …
[HTML][HTML] Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entry
OF Brandenberg, C Magnus, P Rusert… - PLoS …, 2015 - journals.plos.org
HIV-1 enters target cells by virtue of envelope glycoprotein trimers that are incorporated at
low density in the viral membrane. How many trimers are required to interact with target cell …
low density in the viral membrane. How many trimers are required to interact with target cell …
MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
Interference with virus entry is known to be the principle mechanism of HIV neutralization by
antibodies, including 2F5 and 4E10, which bind to the membrane-proximal external region (…
antibodies, including 2F5 and 4E10, which bind to the membrane-proximal external region (…
[HTML][HTML] Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity
…, S Epp, ME Sickmann, MM Schanz, P Rusert… - Nature …, 2021 - nature.com
Determination of SARS-CoV-2 antibody responses in the context of pre-existing immunity to
circulating human coronavirus (HCoV) is critical for understanding protective immunity. Here …
circulating human coronavirus (HCoV) is critical for understanding protective immunity. Here …
Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies
P Rusert, A Krarup, C Magnus… - Journal of Experimental …, 2011 - rupress.org
The HIV-1 envelope trimer adopts a quaternary conformation that effectively shields
neutralization-sensitive domains and thus represents a major obstacle for natural and vaccine-…
neutralization-sensitive domains and thus represents a major obstacle for natural and vaccine-…
[HTML][HTML] Capacity of broadly neutralizing antibodies to inhibit HIV-1 cell-cell transmission is strain-and epitope-dependent
…, C Magnus, M Schanz, J Weber, T Uhr, P Rusert… - PLoS …, 2015 - journals.plos.org
An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for
HIV-1 vaccine development and novel therapeutics. Here, we systematically explored the …
HIV-1 vaccine development and novel therapeutics. Here, we systematically explored the …